Aislinn Antrim is a journalist for Pharmacy Times, writing for both AJMC - The American Journal of Managed Care and Pharmacy Times. Her articles focus on the latest developments in cancer treatments, specifically in breast cancer, as well as advancements in immunotherapy and the impact of obesity on cancer. Aislinn aims to provide valuable insights and information to healthcare professionals and patients in the field of oncology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Aislinn focuses on health, healthcare & pharmaceuticals, and scientific topics with an emphasis on breast cancer treatment and immunotherapy. Her articles often cite data to support the insights provided. When reaching out to her, ensure that you have access to reliable data and can provide evidence-based perspectives.
Given Aislinn's focus on clinical trials and developments in breast cancer treatment, she would be interested in pitches related to cutting-edge research findings or innovations in these areas. If your pitch is related to any of the specific topics she covers (such as HIV care or vaccines), make sure it includes substantial data-driven insights.
While there is no specified geographic focus for Aislinn’s coverage, her interest lies primarily in evidence-based research and advancements within the healthcare industry without a clear regional limitation.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Aislinn Antrim, Cameron Santoro
Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, University of Washington, dissects the limited data on T-cell therapies for multiple myeloma, infectious complications, and access to specialized treatment centers.
By: Aislinn Antrim, Cameron Santoro
Ashraf Badros, MB, ChB, professor at the University of Maryland School of Medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in Oncology, compares the AURIGA trial with other studies on maintenance therapy for patients with multiple myeloma.
By: Aislinn Antrim
Minimal residual disease has been a major topic of discussion during the IMS 2024 Annual Meeting.
By: Cameron Santoro, Aislinn Antrim
Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead investigator of the CARTITUDE-4 study, presented updated data at the 2024 International Myeloma Society conference.
By: Aislinn Antrim
Eligible patients can receive a 30-day supply of covered drugs and medical supplies that can be renewed every 30 days for as long as an Emergency Prescription Assistance Program (EPAP) is active.
By: Aislinn Antrim
This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen. Marstacimab-hncq can offer a subcutaneous treatment option with a once-weekly dosing schedule and minimal required preparation for each individual administration, potentially improving ease of use for patients.
With COVID-19, influenza, respiratory syncytial virus (RSV), and other viruses now circulating, the time for pharmacists to get up to date on the latest vaccine recommendations is now.
By: Aislinn Antrim
Changing the way pharmacists and pharmacy staff think about themselves is key, although providers, payers, and patients must also change how they view the value of pharmacy services.
By: Aislinn Antrim
Nationally, 7 million women live in maternal health deserts, defined as counties with limited or no available obstetric care.
By: Aislinn Antrim
Nearly 19,000 independent pharmacies continue to work across the country, with more than 200,000 employees and millions of patients.
(833) 317-6278 
